| Topic | Key finding | Evidence type (review/primary/human/in vitro/model) | PMID if present in text (otherwise DOI) | Publication year | URL | PaperQA citation id |
|---|---|---|---|---|---|---|
| Entity mapping | GNAS-related pituitary adenoma is best mapped to a somatotroph or mammosomatotroph pituitary neuroendocrine tumor (PitNET) with activating somatic GNAS mutation; these tumors are a major molecular cause of acromegaly rather than a distinct broadly used clinicopathologic name (pqac-00000002, pqac-00000008) | Review; human clinical/genetic synthesis | 10.3389/fendo.2026.1736208 | 2026 | https://doi.org/10.3389/fendo.2026.1736208 | pqac-00000002 |
| Disease-target mapping | Open Targets links GNAS to pituitary gland adenoma, growth hormone-producing pituitary gland adenoma, and mixed somatotroph-lactotroph pituitary gland adenoma, supporting entity alignment with GH-lineage PitNETs (pqac-00000000) | Database association; human literature-backed | N/A | N/A | https://platform.opentargets.org/ | pqac-00000000 |
| Gene/function | GNAS encodes the stimulatory G-protein alpha subunit (Gsα); activating variants impair intrinsic GTPase activity, constitutively activating adenylyl cyclase/cAMP signaling that promotes GH secretion and cell proliferation (pqac-00000002, pqac-00000007) | Review; mechanistic; human/genetic | 10.3389/fendo.2026.1736208 | 2026 | https://doi.org/10.3389/fendo.2026.1736208 | pqac-00000002 |
| Hotspot variants | Recurrent somatic hotspot mutations primarily affect residues R201 and Q227; these stabilize Gsα in its active conformation and inhibit GTPase activity (pqac-00000003, pqac-00000009) | Review; mechanistic; human tumor genetics | 10.3390/medicina59040812 | 2023 | https://doi.org/10.3390/medicina59040812 | pqac-00000003 |
| Variant examples | Explicit hotspot examples include p.R201C and p.R201S in GNAS; table/figure evidence also identifies R201 and Q227 as the key mutational hotspots in PitNETs (pqac-00000007, pqac-00000009) | Review; human tumor genetics | 10.3390/cancers15235685 | 2023 | https://doi.org/10.3390/cancers15235685 | pqac-00000007 |
| Prevalence in acromegaly cohorts | Aggregate prevalence of somatic GNAS mutations in acromegaly was 38% in a structured review and 41% in one institutional series (pqac-00000002) | Systematic review of observational human studies | 10.3389/fendo.2026.1736208 | 2026 | https://doi.org/10.3389/fendo.2026.1736208 | pqac-00000002 |
| Prevalence in GH-secreting tumors | Multiple reviews report somatic GNAS mutations in ~30–40% or ~35–40% of sporadic GH-secreting/somatotroph pituitary tumors (pqac-00000003, pqac-00000004, pqac-00000006) | Review and primary-supported summary; human | 10.3390/medicina59040812 | 2023 | https://doi.org/10.3390/medicina59040812 | pqac-00000003 |
| Current cohort statistic | In a Chinese surgical acromegaly cohort, 44.3% (43/97) of tumors had somatic GNAS hotspot mutations (pqac-00000001) | Human cohort study | 10.1530/ec-24-0266 | 2025 | https://doi.org/10.1530/ec-24-0266 | pqac-00000001 |
| Core phenotype | GNAS-mutant pituitary tumors are typically GH-secreting somatotroph PitNETs causing acromegaly, with elevated IGF-1 and failure of GH suppression on oral glucose testing (pqac-00000004, pqac-00000006) | Primary and review; human clinical | 10.1186/s12967-024-05736-0 | 2024 | https://doi.org/10.1186/s12967-024-05736-0 | pqac-00000006 |
| Histopathology association | GNAS-positive tumors are frequently densely granulated and, in some institutional series, often classified as mammosomatotroph adenomas (pqac-00000001, pqac-00000002, pqac-00000005) | Review; human pathology correlation | 10.3390/cimb46080538 | 2024 | https://doi.org/10.3390/cimb46080538 | pqac-00000005 |
| Tumor size/invasion | Across studies, GNAS-mutant tumors are more consistently reported to be smaller and possibly less invasive than GNAS-wild-type tumors (pqac-00000002, pqac-00000004) | Systematic review and primary; human/model | 10.3389/fendo.2026.1736208 | 2026 | https://doi.org/10.3389/fendo.2026.1736208 | pqac-00000002 |
| Clinical behavior in cohort | In one cohort, mutation-positive patients had smaller tumors (1.75 ± 0.83 vs 2.23 ± 0.89 cm) and higher GH secretion per unit tumor volume than mutation-negative patients (pqac-00000001) | Human cohort study | 10.1530/ec-24-0266 | 2025 | https://doi.org/10.1530/ec-24-0266 | pqac-00000001 |
| Secretory phenotype | GNAS-mutant tumors may show greater GH secretory capacity and higher IGF-1 at diagnosis, although not all studies agree (pqac-00000001, pqac-00000005) | Human cohort/review | 10.1530/ec-24-0266 | 2025 | https://doi.org/10.1530/ec-24-0266 | pqac-00000001 |
| Treatment-response signal | Several reports note greater acute GH suppression with octreotide and sometimes better somatostatin analogue responsiveness in GNAS-mutant tumors, but long-term biochemical control with SRLs is not consistently improved across studies (pqac-00000002, pqac-00000003) | Systematic review; human therapeutic correlation | 10.3389/fendo.2026.1736208 | 2026 | https://doi.org/10.3389/fendo.2026.1736208 | pqac-00000002 |
| Diagnostics | Hotspot variants are readily detectable in clinical samples by Sanger sequencing or NGS; PCR sequencing is also used in GH-producing pituitary adenoma studies (pqac-00000008, pqac-00000004) | Review and primary; human molecular diagnostics | 10.3390/cancers15235685 | 2023 | https://doi.org/10.3390/cancers15235685 | pqac-00000008 |
| Mechanistic downstream biology | A 2024 primary study found MEG3 upregulation in GNAS-mutant GH pituitary adenomas; MEG3 reduced invasion via inhibition of EMT and Wnt/β-catenin signaling, supporting a mechanistic explanation for lower invasiveness (pqac-00000004) | Primary; human tumors, in vitro GH3 cells, mouse xenograft model | 10.32604/or.2024.046007 | 2024 | https://doi.org/10.32604/or.2024.046007 | pqac-00000004 |
| Syndromic relationship | Postzygotic activating GNAS mutations also cause McCune-Albright syndrome, which can include pituitary GH excess; this is related biology but distinct from the usual sporadic somatic tumor setting (pqac-00000003, pqac-00000001) | Review; human syndromic genetics | 10.3390/medicina59040812 | 2023 | https://doi.org/10.3390/medicina59040812 | pqac-00000003 |


*Table: This table summarizes the main evidence linking activating GNAS hotspot mutations to GH-lineage pituitary adenomas/PitNETs, especially somatotroph and mammosomatotroph tumors causing acromegaly. It highlights entity mapping, recurrent variants, mutation frequencies, phenotype associations, and the current state of treatment-response evidence.*